Currently the director of the Aaron Diamond AIDS Research Center at Rockefeller University in New York, Ho is also leading the ongoing Phase II clinical trials for TMB-355 from behind the scenes. TaiMed Biologics, a local firm established in September 2007, acquired the drug's patent from Genentech (the US's first biotechnology company, founded in 1976) for US $ 50 million in cash and US $ 50 million in stock.
何大一現任紐約洛克斐勒大學艾倫・戴蒙德愛滋病研究中心主任，而正在進行第二期臨床試驗的 TMB-355，正是透過他的牽線，由 2007 年 9 月成立的宇昌生技，以現金 5,000 萬美元外加 5,000 萬美元等值股票，向 1976 年創立的全美第一家生技公司 Genentech 買進專利。